In a significant regulatory development, South Korea’s Ministry of Food and Drug Safety has announced its intention to approve the nation’s first abortion pill by early 2027. This move addresses the legislative gap created by the 2019 Constitutional Court ruling that invalidated South Korea’s longstanding criminal abortion ban. The decision aims to establish a structured medical framework for abortion, previously challenged by unregulated methods. Details on this development can be found in the JURIST coverage.
The medication, consisting of a combination of mifepristone and misoprostol, will initially be prescribed and administered by doctors directly at hospitals for the first two years. Following this period, South Korea plans to transition to a prescription and pharmacy-based dispensation system. This approach aligns with Prime Minister Han Seong-sook’s goal of providing women with safe and verified medical alternatives to unauthorized online drug procurement.
Despite the Ministry’s plans, the proposed nine-week usage limit for the medication is shorter than the twelve-week window recommended by the World Health Organization (WHO). This discrepancy, according to Shin Jun-su of the Ministry of Food and Drug Safety, arises from the clinical trial data specific to this application. The WHO provides guidelines for the use of such drugs, outlining safety standards recognized globally.
Since the 2019 court ruling, South Korea’s legislative body has faced criticism for its failure to revise abortion laws in alignment with contemporary health standards. This inaction has prompted women to seek unauthorized medical solutions, a trend the government hopes to counter with this new policy framework. Amnesty International has highlighted the ongoing legal challenges, focusing on the impact of legislative delays on women’s health and rights.
The introduction of abortion pills has received a mixed response. Advocates, including the Korea Women’s Associations United, have welcomed the move as a critical step towards ensuring safer abortion access, urging expedited implementation and insurance coverage. However, opposition from groups such as the Catholic Bishops’ Conference of Korea underscores the societal divide, as religious organizations have raised ethical concerns and even planned legal challenges to the drug’s approval.
As of 2024, approximately 101 countries around the world allow the use of abortion pills, reflecting a broader international trend toward more accessible reproductive health care. South Korea’s plan, while progressive, highlights ongoing debates about women’s rights, public health, and legislative responsibility.